| P2093 | author name string | Kimford J Meador | |
| | Benzi M Kluger | |
| P2860 | cites work | Antiepileptic drugs and apoptotic neurodegeneration in the developing brain | Q24538604 |
| | Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies | Q24623356 |
| | The longer term outcome of children born to mothers with epilepsy | Q24671544 |
| | Disparities in rates of unintended pregnancy in the United States, 1994 and 2001 | Q28245779 |
| | The neurobiology of antiepileptic drugs | Q28267900 |
| | Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene | Q28376491 |
| | Disparities in Rates of Unintended Pregnancy In the United States, 1994 and 2001 | Q29391257 |
| | Wnt signaling: a common theme in animal development | Q29547527 |
| | Safety of the newer antiepileptic drug oxcarbazepine during pregnancy | Q33217593 |
| | Medical genetics: 1. Clinical teratology in the age of genomics | Q33895431 |
| | Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. | Q33976947 |
| | Folate and neural tube defects | Q34001826 |
| | Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women | Q34135348 |
| | Vitamin K in neonates: how to administer, when and to whom | Q34163221 |
| | Verification of the fetal valproate syndrome phenotype | Q34166934 |
| | Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry | Q34203694 |
| | Genetics of craniofacial development and malformation | Q34271559 |
| | Molecular basis of environmentally induced birth defects. | Q34504046 |
| | Erratum to "Safety of zonisamide therapy: prospective follow-up survey.". | Q48415517 |
| | Neurodevelopment after in utero exposure to phenytoin and carbamazepine. | Q52214200 |
| | Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. | Q53239832 |
| | Epilepsy and Pregnancy: A Report from the Oxford Record Linkage Study | Q57386258 |
| | Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects | Q68041646 |
| | Guidelines for the care of women of childbearing age with epilepsy. Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy | Q72829376 |
| | Is the common 677C-->T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis | Q73152143 |
| | Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy | Q74526092 |
| | ON THE PROBLEM OF FETAL DAMAGE DURING PREGNANCY CAUSED BY INTAKE OF ANTICONVULSANTS | Q76652148 |
| | A maternal complex partial seizure in labor can affect fetal heart rate | Q77332547 |
| | Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology | Q77441481 |
| | The AED (antiepileptic drug) pregnancy registry: a 6-year experience | Q80098015 |
| | [Topiramate and pregnancy. Neonate with bone anomalies] | Q81339977 |
| | In utero antiepileptic drug exposure: fetal death and malformations | Q34555052 |
| | Genetic predisposition to phenytoin-induced birth defects | Q34558227 |
| | Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing? | Q34969670 |
| | Pregnancy in the woman with epilepsy: maternal and fetal outcomes | Q35045080 |
| | Epilepsy and pregnancy: Report of an Epilepsy Research Foundation Workshop | Q35048887 |
| | The importance of monotherapy in pregnancy | Q35149580 |
| | Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth | Q35439268 |
| | Pregnancy and the risk of teratogenicity | Q35486681 |
| | Management issues for women with epilepsy: neural tube defects and folic acid supplementation | Q35540886 |
| | Antiepileptic drug pharmacokinetics during pregnancy and lactation | Q35540892 |
| | Malformation rates in children of women with untreated epilepsy: a meta-analysis | Q35645910 |
| | A review of vitamin K, epilepsy and pregnancy | Q35909493 |
| | Pregnancy in women who have epilepsy | Q35913468 |
| | Mechanisms of teratogenesis: folic acid and antiepileptic therapy | Q36059284 |
| | Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register | Q36142531 |
| | Bipolar disorder in women: reproductive events and treatment considerations | Q36181505 |
| | Treating mood disorders during pregnancy: safety considerations | Q36209599 |
| | Birth defects after prenatal exposure to antiepileptic drugs | Q36292532 |
| | Antiepileptic drugs and the developing brain | Q36359030 |
| | Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin--developmental effects of valproic acid | Q36370360 |
| | Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy | Q36452208 |
| | Antiepileptic drugs and neurodevelopment | Q36527829 |
| | Seizures and antiepileptic drugs: does exposure alter normal brain development? | Q36698616 |
| | The fetal hydantoin syndrome | Q39338123 |
| | Cerebral dysgenesis. An overview. | Q40585550 |
| | Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. | Q40748918 |
| | Hereditary factors in the etiology of neural tube defects. Results of a survey | Q41067091 |
| | The teratogenicity of anticonvulsant drugs | Q41923758 |
| | In utero exposure to phenobarbital and intelligence deficits in adult men. | Q42274375 |
| | Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy | Q42275048 |
| | Valproic acid and spina bifida | Q42591919 |
| | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register | Q43405933 |
| | Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality | Q43650811 |
| | Lamotrigine and the risk of malformations in pregnancy | Q43669569 |
| | Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study | Q43680169 |
| | Pattern of malformations in the children of women treated with carbamazepine during pregnancy | Q43779596 |
| | Increased rate of major malformations in offspring exposed to valproate during pregnancy | Q43905735 |
| | Major malformations in offspring of women with epilepsy | Q44324825 |
| | Clonazepam use in pregnancy and the risk of malformations | Q45030769 |
| | Antiepileptic drug use of women with epilepsy and congenital malformations in offspring | Q46546783 |
| | Maternal valproate dosage and foetal malformations | Q46648132 |
| | Fetal rat brain damage caused by maternal seizure activity: prevention by magnesium sulfate | Q48090523 |
| P433 | issue | 3 | |
| P921 | main subject | teratogenicity | Q56246640 |
| P304 | page(s) | 328-335 | |
| P577 | publication date | 2008-07-24 | |
| P1433 | published in | Seminars in Neurology | Q15761563 |
| P1476 | title | Teratogenicity of antiepileptic medications | |
| P478 | volume | 28 | |